The Use of ACE inhibitor/ARB in SARS-CoV-2 Patients: A Comprehensive Narrative Review

Authors

  • Timotius Ivan Hariyanto Medical Doctor, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman street, Karawaci, Tangerang, Indonesia 15811 https://orcid.org/0000-0002-1748-9776
  • Karunia Valeriani Japar Medical Doctor, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman street, Karawaci, Tangerang, Indonesia 15811
  • Vika Damay Medical Doctor, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman street, Karawaci, Tangerang, Indonesia 15811
  • Felix Kwenandar Medical Doctor, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman street, Karawaci, Tangerang, Indonesia 15811
  • Novia Lauren Sieto Medical Doctor, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman street, Karawaci, Tangerang, Indonesia 15811 and Mochtar Riady Institute of Nanotechnology, Boulevard Jendral Sudirman street, Karawaci, Tangerang, Indonesia 15811
  • Andree Kurniawan Medical Doctor, Internal Medicine Specialist, Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman street, Karawaci, Tangerang, Indonesia 15811 https://orcid.org/0000-0002-5219-9029

DOI:

https://doi.org/10.3126/ajms.v11i6.29911

Keywords:

COVID-19, SARS-CoV-2, ACE2, ACE inhibitors, Angiotensin II

Abstract

The three most common comorbidities that are associated with increased mortality in COVID-19 patients are Hypertension, Diabetes, and Cardiovascular disease, Angiotensin-converting enzyme (ACE) inhibitors and Angiotensin II receptor blockers (ARB) are the drugs most commonly prescribed for the management of these diseases. Recent experimental study in animals and humans have found that SARS-CoV-2 uses ACE2 as the receptors for entry. Moreover, in an animal study, the use of ACE inhibitor/ARB increases the level of ACE2 expression that can lead to increased SARS-CoV-2 infectivity. On the other side, some evidences suggest that the ACE2 receptor is not necessary for SARS-CoV-2 entry into the cell and suggested that there is a cofactor that play part. Experimental studies in humans also showed that there is no association between ACE inhibitor/ARB with SARS-CoV-2 infectivity and mortality. In conclusion, there is still insufficient data to stop the use of inhibitor/ARB in SARS-CoV-2 patients. Therefore, we suggested that in line with the recommendations from ESC and AHA/ACC, the use of these two drugs in SARS-CoV-2 patients with cardiovascular comorbidity should still be continued.

Downloads

Download data is not yet available.
Abstract
577
PDF
563

Downloads

Published

2020-11-01

How to Cite

Hariyanto, T. I., Japar, K. V., Damay, V., Kwenandar, F., Sieto, N. L., & Kurniawan, A. (2020). The Use of ACE inhibitor/ARB in SARS-CoV-2 Patients: A Comprehensive Narrative Review. Asian Journal of Medical Sciences, 11(6), 113–120. https://doi.org/10.3126/ajms.v11i6.29911

Issue

Section

Review Articles